We are live on
!
Find out more
X
Xponance Portfolio holdings
AUM
$16.3B
1-Year Est. Return
44.61%
This Fund
S&P 500
This Quarter
Est. Return
+6.44%
1 Year Est. Return
+44.61%
3 Year Est. Return
+143.93%
5 Year Est. Return
+195.59%
10 Year Est. Return
+501.04%
AUM
$10.4B
AUM Growth
+$576M
(+5.9%)
Cap. Flow
+$80.3M
Cap. Flow
% of AUM
0.78%
Top 10 Holdings %
Top 10 Hldgs %
38.6%
Holding
1,407
New
91
Increased
858
Reduced
433
Closed
18
Avg Time Held
12.2
quarters
Top 10 Avg Time Held
13
quarters
Top 20 Avg Time Held
11.3
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$12.5M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$12.5M |
| 3 |
Meta Platforms (Facebook)
META
|
+$8.69M |
| 4 |
Visa
V
|
+$8.21M |
| 5 |
Amazon
AMZN
|
+$6.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$7.31M |
| 2 |
Verisk Analytics
VRSK
|
+$5.19M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$5.16M |
| 4 |
Gartner
IT
|
+$4.49M |
| 5 |
iShares Russell 1000 Growth ETF
IWF
|
+$3.73M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.83% |
| 2 | Consumer Discretionary | 11.41% |
| 3 | Financials | 11.04% |
| 4 | Healthcare | 10.64% |
| 5 | Communication Services | 9.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1376
Taysha Gene Therapies
TSHA
$1.37B
| $21.8K | ﹤0.01% |
+10,869
| New | +$23.8K |
2024 Q3
0 quarters
|
|
1377
GrafTech
EAF
$223M
| $21.3K | ﹤0.01% |
1,616
+103
| +7% | +$859 |
2022 Q2
9 quarters
|
|
1378
SmartRent
SMRT
$224M
| $21.2K | ﹤0.01% |
12,256
| – | – |
2023 Q2
5 quarters
|
|
1379
DELISTED
Esperion Therapeutics
ESPR
| $19.9K | ﹤0.01% |
12,086
-359
| -3% | -$725 |
2024 Q2
1 quarter
|
|
1380
Cerus
CERS
$449M
| $19.5K | ﹤0.01% |
11,234
-226
| -2% | -$474 |
2023 Q2
5 quarters
|
|
1381
DELISTED
Luminar Technologies
LAZR
| $19.5K | ﹤0.01% |
1,448
+43
| +3% | +$780 |
2022 Q2
9 quarters
|
|
1382
Akebia Therapeutics
AKBA
$221M
| $18.1K | ﹤0.01% |
13,701
| – | – |
2024 Q2
1 quarter
|
|
1383
Ocugen
OCGN
$324M
| $16.6K | ﹤0.01% |
16,751
+890
| +6% | +$1.22K |
2024 Q2
1 quarter
|
|
1384
Microvision
MVIS
$37.3M
| $15.2K | ﹤0.01% |
891
+35
| +4% | +$545 |
2023 Q2
5 quarters
|
|
1385
Nektar Therapeutics
NKTR
$1.37B
| $14K | ﹤0.01% |
720
-44
| -6% | -$839 |
2024 Q2
1 quarter
|
|
1386
Lyell Immunopharma
LYEL
$205M
| $13.9K | ﹤0.01% |
503
| – | – |
2023 Q3
4 quarters
|
|
1387
Solid Power
SLDP
$516M
| $13.6K | ﹤0.01% |
+10,099
| New | +$16K |
2024 Q3
0 quarters
|
|
1388
FuelCell Energy
FCEL
$1.27B
| $11.6K | ﹤0.01% |
1,016
+44
| +5% | +$652 |
2021 Q2
13 quarters
|
|
1389
DELISTED
bluebird bio
BLUE
| $6.15K | ﹤0.01% |
592
| – | – |
2024 Q1
2 quarters
|
|
1390
Diodes
DIOD
$4.19B
| – | – |
-2,899
| Closed | -$209K | – |
|
1391
iShares MSCI EAFE Value ETF
EFV
$30.2B
| – | – |
-35,991
| Closed | -$1.76M | – |
|
1392
Guardant Health
GH
$21.7B
| – | – |
-7,479
| Closed | -$216K | – |
|
1393
Helen of Troy
HELE
$672M
| – | – |
-3,210
| Closed | -$298K | – |
|
1394
Helmerich & Payne
HP
$3.89B
| – | – |
-6,163
| Closed | -$223K | – |
|
1395
iShares Core MSCI Emerging Markets ETF
IEMG
$159B
| – | – |
-64,472
| Closed | -$3.18M | – |
|
1396
iRhythm Holdings
IRTC
$3.51B
| – | – |
-1,954
| Closed | -$210K | – |
|
1397
MP Materials
MP
$7.73B
| – | – |
-14,298
| Closed | -$182K | – |
|
1398
Progyny
PGNY
$2.14B
| – | – |
-11,314
| Closed | -$324K | – |
|
1399
Seadrill
SDRL
$2.93B
| – | – |
-4,718
| Closed | -$243K | – |
|
1400
SITE Centers
SITC
$162M
| – | – |
-15,468
| Closed | -$175K | – |
|
Similar funds
PCM
LPC
MFG
PAM
BS
BBVA
NMO
PAS
Xponance's Q3 2024 Portfolio in Review
As of Q3 2024, Xponance held 1,407 positions worth $10.4B, up 5.9% from $9.78B the previous quarter. Its ten largest holdings account for 39% of the portfolio.
Xponance's Q3 2024 filing shows 91 new, 858 increased, 433 reduced and 18 closed positions. Its largest new stake was Smurfit Westrock: 106,066 shares worth $5.24M. The largest sale was Eli Lilly, an estimated $7.31M.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 37% a quarter earlier, followed by Consumer Discretionary and Financials.
- Xponance's largest Q3 2024 buy was Smurfit Westrock: 106,066 shares worth $5.24M.
- Xponance added most to Broadcom in Q3 2024, an estimated $12.5M increase.
- Xponance's biggest Q3 2024 reduction was Eli Lilly, cutting an estimated $7.31M.
- Xponance fully exited Invesco S&P 500 Concentrated QVM ETF in Q3 2024, selling an estimated $3.61M.
- Xponance's ten largest holdings make up 39% of its $10.4B portfolio in Q3 2024.
- Xponance opened 91 new positions and closed 18 in Q3 2024.
- Xponance's portfolio value rose 5.9% quarter-over-quarter to $10.4B.
Based on Xponance's 13F filing for Q3 2024, filed 12 Nov 2024.